ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Kidney Recipients
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 128
- Registration Number
- NCT00384137
A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 706
- Registration Number
- NCT00378690
A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 882
- Registration Number
- NCT00379067
Micafungin Salvage Mono-therapy in Invasive Aspergillosis
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 17
- Registration Number
- NCT00376337
A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 450
- Registration Number
- NCT00374777
Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program
Completed
- Conditions
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 426
- Registration Number
- NCT00371774
A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-08-25
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 246
- Registration Number
- NCT00368706
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1141
- Registration Number
- NCT00353678
Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 62
- Registration Number
- NCT00347048
AMEVIVE® Pregnancy Registry
- First Posted Date
- 2006-06-21
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 3
- Registration Number
- NCT00342862
- Locations
- 🇺🇸
INC Research, Wilmington, North Carolina, United States
© Copyright 2024. All Rights Reserved by MedPath